Purple Biotech announces their novel CAPTN-3 tri-specific antibody platform at EACR 2025. The company focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Their oncology pipeline includes CM24, a humanized monoclonal antibody that blocks CEACAM1 to target multiple cancer indications. NT219, a dual inhibitor small molecule, demonstrated anti-tumor activity in a […]
Tag: antibodies
Analysts’ Insights on BioNTech’s Future
BioNTech, a Germany-based biotech company, is at the forefront of developing cancer therapeutics and vaccines for infectious diseases, including COVID. With a diverse oncology pipeline that includes mRNA-based drugs, cell therapies, bispecific antibodies, and ADCs, BioNTech has established partnerships with major pharmaceutical companies like Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Its COVID vaccine, Comirnaty, […]
Advancing Neurological Disease Treatment with Brain Organoids
Brain organoids represent a cutting-edge tool in the realm of biotechnology and pharmaceuticals, particularly in the study and potential treatment of neurological diseases. ACROBiosystems, a leading enterprise in this field, is dedicated to providing innovative solutions to address challenges from initial discovery to clinical application. Their range of life science tools, including recombinant proteins, antibodies, […]
Aquaporin-4 Antibody Titers Influence Neuromyelitis Optica Relapse
In a groundbreaking study on 171 NMOSD patients, researchers found that a decrease in Aquaporin-4 antibody titers led to a significant reduction in relapse rates. Specifically, 25.7% of patients became AQP4-IgG seronegative, resulting in a remarkable decrease in annualized relapse rate. The decline in AQP4-IgG levels was identified as a protective factor against relapse, highlighting […]
